Title
Značaj galektina-1 kao prognostičkog faktora u lečenju klasičnog Hočkinovog limfoma
Creator
Simonović, Olivera B. 1971-
Copyright date
2017
Object Links
Select license
Autorstvo-Nekomercijalno-Bez prerade 3.0 Srbija (CC BY-NC-ND 3.0)
License description
Dozvoljavate samo preuzimanje i distribuciju dela, ako/dok se pravilno naznačava ime autora, bez ikakvih promena dela i bez prava komercijalnog korišćenja dela. Ova licenca je najstroža CC licenca. Osnovni opis Licence: http://creativecommons.org/licenses/by-nc-nd/3.0/rs/deed.sr_LATN. Sadržaj ugovora u celini: http://creativecommons.org/licenses/by-nc-nd/3.0/rs/legalcode.sr-Latn
Language
Serbian
Cobiss-ID
Theses Type
Doktorska disertacija
description
Datum odbrane: 27.2.2018.
Other responsibilities
mentor
Marjanović, Goran
član komisije
Mačukanović-Golubović, Lana
član komisije
Jevtović-Stoimenov, Tatjana
član komisije
Mihaljević, Biljana
Academic Expertise
Medicinske nauke
University
Univerzitet u Nišu
Faculty
Medicinski fakultet
Group
Katedra za internu medicinu
Alternative title
The importance of galectin-1 as a prognostic factor in the treatment of classical Hodgkinʼs lymphoma
Publisher
[O. B. Simonović]
Format
XVI, 125 listova
description
Biografija: list 125;
Bibliografija: listovi 107-124
description
Internal medicine
Abstract (en)
In classical Hodgkin’s lymphoma (cHL) the existing prognostic
scoring systems do not include markers that adequately reflect the
interaction of malignant Hodgkin and Reed-Sternberg (HRS) cells
and tumor environment. The research objective is to determine the
relationship between serum Galectin-1 (Gal-1) and soluble CD163
(sCD163) and the clinical status of patients with cHL, with special
emphasis on the presence of relapse, progression, or resistance to the
therapy applied. The research included 79 patients. Of this number,
63 were patients with cHL, and the control group consisted of 16
healthy volunteers. The study group of 63 patients with cHL included
a subgroup of newly diagnosed patients without therapy, newly
diagnosed patients with therapy, patients with relapse and progression
of the disease, and primary refractory patients during 2014 and 2015.
Analysis of the levels of sCD163 and sGal-1 within a group of
patients suffering from cHL has shown that the values of both
molecules were higher in relapsed patients and the subgroup with
progressive disease comparing the subgroup of newly diagnosed
patients without therapy or patients with therapy onset. Determination
of Gal-1 and sCD163 levels is simple and reliable analysis that can
contribute to the identification of high-risk patients with cHL, and
deserves inclusion in current prognostic scoring systems.
Authors Key words
Hoĉkinov limfom, Internacionalni prognostiĉki skor, sCD163, Gal-1
Authors Key words
Hodgkin’s lymphoma, International prognostic score, Gal-1, sCD163
Classification
616.42-006.44-08:577.112(043.3)
Subject
B 490
Type
Elektronska teza
Abstract (en)
In classical Hodgkin’s lymphoma (cHL) the existing prognostic
scoring systems do not include markers that adequately reflect the
interaction of malignant Hodgkin and Reed-Sternberg (HRS) cells
and tumor environment. The research objective is to determine the
relationship between serum Galectin-1 (Gal-1) and soluble CD163
(sCD163) and the clinical status of patients with cHL, with special
emphasis on the presence of relapse, progression, or resistance to the
therapy applied. The research included 79 patients. Of this number,
63 were patients with cHL, and the control group consisted of 16
healthy volunteers. The study group of 63 patients with cHL included
a subgroup of newly diagnosed patients without therapy, newly
diagnosed patients with therapy, patients with relapse and progression
of the disease, and primary refractory patients during 2014 and 2015.
Analysis of the levels of sCD163 and sGal-1 within a group of
patients suffering from cHL has shown that the values of both
molecules were higher in relapsed patients and the subgroup with
progressive disease comparing the subgroup of newly diagnosed
patients without therapy or patients with therapy onset. Determination
of Gal-1 and sCD163 levels is simple and reliable analysis that can
contribute to the identification of high-risk patients with cHL, and
deserves inclusion in current prognostic scoring systems.
“Data exchange” service offers individual users metadata transfer in several different formats. Citation formats are offered for transfers in texts as for the transfer into internet pages. Citation formats include permanent links that guarantee access to cited sources. For use are commonly structured metadata schemes : Dublin Core xml and ETUB-MS xml, local adaptation of international ETD-MS scheme intended for use in academic documents.